Company: ARVN
Filing Date: 2025-06-02
Form Type: 8-K
Source: 0001655759-25-000095
Chunk: 0

Company: ARVINAS, INC.
Filing Date: 2025-06-02
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On May 31, 2025, Arvinas, Inc. (the “ Company”), along with Pfizer, Inc. ("Pfizer"), announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant (ARV-471) monotherapy versus fulvestrant in adults with estrogen receptor (“ ER”)-positive (“ ER+”), human epidermal growth factor receptor 2-negative (“ HER2-”) (“ ER+/HER2-”) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (“ CDK”) 4/6 inhibitors and endocrine therapy. These detailed results, which follow the March 11, 2025 announcement of the topline results from the Phase 3 VERITAC-2 clinical trial, were highlighted in the American Society of Clinical Oncology (ASCO®) press briefing and selected for Best of ASCO, and were presented in a late-breaking oral presentation and were simultaneously published in theNew England Journal of Medicine on May 31, 2025. The Company also plans to host a conference call and webcast on June 2, 2025 to review these detailed data.

The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.